Health Care • Medical/Dental Instruments
$23.44 ▲ +0.52
(+2.27%)
MKT CAP: $1.14B • VOL: 418.2K
52W L $19 52W H $48
AORT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $441.3M | $388.5M | $354.0M |
| YoY Revenue Growth % | +13.6% | +9.8% | — |
| Gross Profit | $284.2M | $248.8M | — |
| Gross Margin % | 64.4% | 64.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $33.7M | $38.9M | $5.7M |
| Operating Margin % | 7.6% | 10.0% | 1.6% |
| Net Income (GAAP) | $9.8M | -$13.4M | -$30.7M |
| EBITDA (Normalized) | $65.0M | $47.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $39.9M | $22.2M | $18.8M |
| Capital Expenditures (CapEx) | $39.0M | $11.2M | — |
| Free Cash Flow (FCF) | $839.0K | $11.0M | $18.8M |
| FCF Margin % | 0.2% | 2.8% | 5.3% |
| Return on Invested Capital (ROIC %) | 4.5% | 5.7% | — |
| Cash & Short-Term Equivalents | $64.9M | $53.5M | — |
| Total Debt (Short + Long Term) | $215.1M | $314.2M | — |
| Total Stockholders' Equity | $448.2M | $276.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AORT.